title: The view from managed care pharmacy.
abstract: This stratified, national telephone survey of fifty-one managed care organizations concerns the perspectives of managed care pharmacy directors on pharmacoeconomics, disease management, and the roles of the pharmaceutical industry and the Food and Drug Administration (FDA). Respondents rated clinical effectiveness assessments as most useful, cost-effectiveness assessments second, and quality-of-life assessments as least useful. Peer-reviewed and industry literature were rated as equally important for decision making. Most plans would consider establishing a partnership with a drug company for disease management, if they have not already done so. Most plans (76 percent) support some form of FDA regulation of pharmacoeconomic claims. Conversely, 69 percent favor either no regulation (24 percent) or less stringent regulation (45 percent) than exists today.
authors.affiliation: MEDTAP International, Bethesda, MD, USA.
authors.forename: B R
authors.initials: BR
authors.lastname: Luce
authors.forename: C A
authors.initials: CA
authors.lastname: Lyles
authors.forename: A M
authors.initials: AM
authors.lastname: Rentz
mesh_terms: D003362:Cost-Benefit Analysis; D019468:Disease Management; D004345:Drug Industry; D005569:Formularies as Topic; D019538:Health Care Surveys; D008329:Managed Care Programs / Q000458:organization & administration* / Q000706:statistics & numerical data; D010605:Pharmacy Administration / Q000706:statistics & numerical data*; D014481:United States; D014486:United States Food and Drug Administration